Palantir Technologies Inc. - Class A Common Stock (PLTR)
167.23
+1.37 (0.83%)
NASDAQ· Last Trade: Sep 12th, 12:33 AM EDT
Detailed Quote
Previous Close
165.86
Open
168.10
Bid
167.35
Ask
167.53
Day's Range
165.40 - 168.61
52 Week Range
106.37 - 207.52
Volume
15,451,797
Market Cap
339.05B
PE Ratio (TTM)
269.73
EPS (TTM)
0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
29,348,935
Chart
About Palantir Technologies Inc. - Class A Common Stock (PLTR)
Palantir Technologies is a public software company that specializes in big data analytics and provides platforms for organizations to integrate, visualize, and analyze large amounts of data from disparate sources. Its flagship products, Palantir Gotham and Palantir Foundry, are designed to assist government agencies and commercial enterprises in making data-driven decisions by offering advanced analytical capabilities, collaborative tools, and visualization features. The company has gained prominence for its work with intelligence and defense organizations, as well as its growing presence in various industries such as finance, healthcare, and manufacturing, enabling clients to derive actionable insights and enhance their operational efficiency. Read More
London, UK — Ben Harrison Raven Hung, founder of Investment Success Ben Academy Ltd , has risen to prominence as one of the youngest and most successful traders in the UK, earning a reputation for bold predictions, disciplined strategies, avoiding naysayers and remarkable returns.
Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
President and CEO Jacqueline Shea
Palantir Technologies (NASDAQ:PLTR) used its AIPCon event to highlight customer deployments of its Foundry, Ontology and Artificial Intelligence Platform products across supply chains, aviation safety, defense manufacturing, insurance, media, pharmaceuticals and industrial operations. Speakers repea
What Happened? Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 8.5% in the afternoon session after Deutsche Bank initiated coverage on ...
Palantir won a $127 million production contract as prime contractor for the Army's TITAN ground stations, expanding its defense role even as PLTR shares pulled back after August's rally.
Inovio Pharmaceuticals (NASDAQ:INO) is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
Shea described Inovio as a clinical-stage company d
Palantir expands its AI footprint via new enterprise deployments, a free cybersecurity initiative, and an upgraded sovereign AI partnership with Fujitsu.
Today, Method Security and Palantir Technologies (NASDAQ: PLTR) announced the Cardinal Program, an initiative to strengthen national cyber resilience through safe, autonomous red teaming.
Palantir Technologies Inc. (NASDAQ: PLTR) and Fujitsu Limited today announced the renewal of their strategic partnership, with a deeper investment in the capabilities needed to help enterprises in Japan and around the world. In connection with the partnership, Fujitsu has signed a new agreement with Palantir Technologies Japan KK for Palantir AIP and Palantir Foundry and will serve as a Global FDE Partner.
Palantir Technologies Inc. (NASDAQ: PLTR) and NVIDIA (NASDAQ: NVDA) today announced a collaboration to bring sovereign AI to critical supply chains, starting with NVIDIA’s own operations.
Since March 2026, RLI has been in a holding pattern, posting a small return of 0.8% while floating around $61.22. The stock also fell short of the S&P 500’s ...
Limbach’s stock price has taken a beating over the past six months, shedding 39.3% of its value and falling to $48.84 per share. This was partly due to its s...
